Recruitment of Mycobacterium tuberculosis specific CD4 + T cells to the site of infection for diagnosis of active tuberculosis

Similar documents
Diagnosis of Central Nervous System Tuberculosis by T-Cell-Based Assays on Peripheral Blood and Cerebrospinal Fluid Mononuclear Cells

MAIT cell function is modulated by PD-1 signaling in patients with active

In our paper, we suggest that tuberculosis and sarcoidosis are two ends of the same spectrum. Given the pathophysiological and clinical link between

[DOI] /j.issn

Supplemental Figure 1. Gating strategies for flow cytometry and intracellular cytokinestaining

Supplementary webappendix

Potential Role of Immunodiagnosis for Pulmonary Tuberculosis Using Induced Sputum Cells

CHAPTER 3: DEFINITION OF TERMS

Let s Talk TB A Series on Tuberculosis, A Disease That Affects Over 2 Million Indians Every Year

University of Groningen

Organic dust-induced interleukin-12 production activates T- and natural killer cells

Detailed step-by-step operating procedures for NK cell and CTL degranulation assays

TB Intensive San Antonio, Texas December 1-3, 2010

TB & HIV CO-INFECTION IN CHILDREN. Reené Naidoo Paediatric Infectious Diseases Broadreach Healthcare 19 April 2012

APPLICATION OF IMMUNO CHROMATOGRAPHIC METHODS IN PLEURAL TUBERCULOSIS

Diagnosis of tuberculosis: principles and practice of using interferon- release assays (IGRAs)

Peripheral T Cell Cytokine Responses for Diagnosis of Active Tuberculosis

Evaluation of Mycobacterium tuberculosis specific T cell response to ESAT-6 and PPD antigen with ELISPOT assay

Tuberculosis Intensive

Characteristics of Mycobacterium

Latent Tuberculosis Infections Controversies in Diagnosis and Management Update 2016

Clinical application of a rapid lung-orientated immunoassay in individuals with possible tuberculosis

Communicable Disease Control Manual Chapter 4: Tuberculosis

Interferon γ regulates idiopathic pneumonia syndrome, a. Th17 + CD4 + T-cell-mediated GvH disease

Tuberculosis What you need to know. James Zoretic M.D., M.P.H. Regions 2 and 3 Director

Diagnostic Value of ELISPOT Technique for Osteoarticular Tuberculosis

Preface. Date: May 1, 2003 Vol.1/MX-2/05/03

2017 Vol. 23 No. 2 PP ISSN (Print)

Identifying TB co-infection : new approaches?

Tuberculosis Pathogenesis

Title: Role of Interferon-gamma Release Assays in the Diagnosis of Pulmonary Tuberculosis in Patients with Advanced HIV infection

Improved diagnosis of extrapulmonary tuberculosis by antigen detection using immunochemistry-based assay. Tehmina Mustafa

Diagnostic Value of Elisa Serological Tests in Childhood Tuberculosis

Rapid antigen-specific T cell enrichment (Rapid ARTE)

Didactic Series. Latent TB Infection in HIV Infection

The Diagnosis of Active TB. Deborah McMahan, MD TB Intensive September 28, 2017

Tuberculosis. By: Shefaa Q aqa

ORIGINAL ARTICLE. Clinical evaluation of QuantiFERON TB-2G test for immunocompromised patients

Interferon gamma release assays and the NICE 2011 guidelines on the diagnosis of latent tuberculosis

Andrew Ramsay Secretary STP Working Group on New Diagnostics WHO/TDR 20, Avenue Appia CH-1211, Geneva 27, Switzerland

International Journal of Innovative Research in Medical Science (IJIRMS)

Tuberculosis (TB) remains a major cause of. Use of a T-cell interferon-c release assay for the diagnosis of tuberculous pleurisy

of clinical laboratory diagnosis in Extra-pulmonary Tuberculosis

Clinical evaluation of QuantiFERON TB-2G test for immunocompromised patients

Effect of prolonged incubation time on the results of the QuantiFERON TB Gold In-Tube assay for the diagnosis of latent tuberculosis infection

Optimizing Intracellular Flow Cytometry:

Research Article Cytokines as Biomarkers in the Diagnosis of MDR TB Cases

Gladstone Institutes, University of California (UCSF), San Francisco, USA

Direct ex vivo characterization of human antigen-specific CD154 + CD4 + T cells Rapid antigen-reactive T cell enrichment (Rapid ARTE)

TB In Detroit 2011* Early TB: Smudge Sign. Who is at risk for exposure to or infection with TB? Who is at risk for TB after exposure or infection?

SUPPLEMENTARY INFORMATION

TB Laboratory for Nurses

T-CELL RESPONSES ASSESSED USING IGRA AND TST ARE NOT CORRELATED WITH AFB GRADE AND CHEST RADIOGRAPH IN PULMONARY TUBERCULOSIS PATIENTS

The immunologic paradox in the diagnosis of

New Tuberculosis Guidelines. Jason Stout, MD, MHS

Variation in T-SPOT.TB spot interpretation between independent observers of different laboratories

ESCMID Online Lecture Library. by author

SOLUBLE TRIGGERING RECEPTOR EXPRESSED ON MYELOID. CELLS (s-trem-1) IN SPUTUM OF PATIENTS WITH COMMUNITY-ACQUIRED PNEUMONIA OR PULMONARY

Making the Diagnosis of Tuberculosis

Pathology of pulmonary tuberculosis. Dr: Salah Ahmed

Research Article Interferon-Gamma Release Assay Performance of Cerebrospinal Fluid and Peripheral Blood in Tuberculous Meningitis in China

Clinical Utility of the QuantiFERON TB-2G Test for Elderly Patients With Active Tuberculosis*

Diagnostic Usefulness of a T-cell-based Assay for Extrapulmonary Tuberculosis in Immunocompromised Patients

Technical Bulletin No. 172

What the Primary Physician Should Know about Tuberculosis. Topics for Discussion. Life Cycle of M. tuberculosis

MODULE ONE" TB Basic Science" Treatment Action Group TB/HIV Advocacy Toolkit

Impact of a T cell-based blood test for tuberculosis infection on clinical decision-making in routine practice

Technical Resources. BD Immunocytometry Systems. FastImmune Intracellular Cytokine Staining Procedures

Received 21 August 2007/Returned for modification 14 September 2007/Accepted 11 November 2007

Sponsored document from The Journal of Infection

Targeted Testing and the Diagnosis of. Latent Tuberculosis. Infection and Tuberculosis Disease

TUBERCULOSIS. By Dr. Najaf Masood Assistant Prof Pediatrics Benazir Bhutto Hospital Rawalpindi

Mycobacterial Infections: What the Primary Provider Should Know about Tuberculosis

TUBERCULOSIS. Pathogenesis and Transmission

What the Primary Physician Should Know about Tuberculosis. Topics for Discussion. Global Impact of TB

Dr Francis Ogaro MTRH ELDORET

Respiratory System الفريق الطبي االكاديمي

SWABCHA Fact Sheet: Tuberculosis (TB)

CDPH - CTCA Joint Guidelines Guideline for Micobacteriology Services In California

Nucleic Acid Amplification Test for Tuberculosis. Heidi Behm, RN, MPH Acting TB Controller HIV/STD/TB Program Oregon, Department of Health Services

TB Prevention Who and How to Screen

(b) Describe the role of antigen presentation in the body s specific immune response to infection by viruses. (4)

Diagnostic accuracy of T-cell interferon-gamma release assays in. tuberculous pleurisy: a meta-analysis *

TB: A Supplement to GP CLINICS

TB Intensive San Antonio, Texas November 11 14, 2014

In vitro human regulatory T cell expansion

Page 1 of 2. Product Information Contents: ezkine Th1 Activation 2 Whole Blood Intracellular Cytokine Kit

Pediatric TB Lisa Armitige, MD, PhD September 28, 2011

INFECTION/ INFLAMMATION

Barbara J Seaworth MD Medical Director, Heartland National TB Center Professor, Internal Medicine and Infectious Disease UT Health Northeast

Clinical and Cerebrospinal Fluid Abnormalities as Diagnostic Tools of Tuberculous Meningitis

Supplementary Figures

CHAPTER:1 TUBERCULOSIS. BY Mrs. K.SHAILAJA., M. PHARM., LECTURER DEPT OF PHARMACY PRACTICE, SRM COLLEGE OF PHARMACY

Laboratory Diagnostic Techniques. Hugo Donaldson Consultant Microbiologist Imperial College Healthcare NHS Trust

TB the basics. (Dr) Margaret (DHA) and John (INZ)

International Journal of Health Sciences and Research ISSN:

TB Intensive Houston, Texas October 15-17, 2013

TB Intensive Houston, Texas. Childhood Tuberculosis Kim Connelly Smith. November 12, 2009

Monica Manandhar. 2 ND YEAR RESEARCH ELECTIVE RESIDENT S JOURNAL Volume V, A. Study Purpose and Rationale

Transcription:

Original Article doi: 10.1111/j.1365-2796.2008.02012.x Recruitment of Mycobacterium tuberculosis specific CD4 + T cells to the site of infection for diagnosis of active tuberculosis J. Nemeth 1,2, H.-M. Winkler 1, R. H. Zwick 3, R. Rumetshofer 3, P. Schenk 4, O. C. Burghuber 3, W. Graninger 1, M. Ramharter 1 & S. Winkler 1 From the 1 Division of Infectious Diseases and Tropical Medicine, Department of Medicine I, Medical University of Vienna, Vienna, Austria; 2 Department of Medicine, Universitätsspital Basel, Basel, Switzerland; 3 Department of Respiratory and Critical Care Medicine, Otto-Wagner Hospital; and 4 Division of Respiratory Medicine, Department of Medicine III, Medical University of Vienna, Vienna, Austria Abstract. Nemeth J, Winkler H-M, Zwick RH, Rumetshofer R, Schenk P, Burghuber OC, Graninger W, Ramharter M, Winkler S (Medical University of Vienna, Vienna, Austria, Universitätsspital Basel, Basel, Switzerland, Otto-Wagner Hospital; Medical University of Vienna, Vienna; Austria). Recruitment of Mycobacterium tuberculosis specific CD4 + T cells to the site of infection for diagnosis of active tuberculosis. J Intern Med 2008; doi: 10.1111/j.1365-2796.2008.02012.x Context. Accurate and early diagnosis of active tuberculosis (TB) is problematic as current diagnostic methods show low sensitivity (acid-fast bacilli smears), are time-consuming (culture of biological samples) or show variable results [Mycobacterium tuberculosis (MTB)-specific PCR]. Objectives. In the course of infection, MTB-specific T cells clonally expand at the site of infection and may thus be used as diagnostic marker for active disease. obtained from peripheral blood and the site of disease in 25 patients with suspected TB was assessed (n =11, bronchoalveolar lavage; n = 7, pleural fluid; n = 1, ascites; n = 1, joint fluid; n = 5, cerebrospinal fluid). Results. Amongst 15 patients who showed proven active TB infection, a striking increase of MTB-specific T cells was detected at the site of infection compared with peripheral blood (median increase: 28.5-fold, range: 7.25 531 fold; median of IFN-c-producing CD4 + T cells from blood: 0.02%, range: 0 0.52%; median of IFN-c-producing CD4 + T cells from the site of infection: 1.81%, range: 0.29 6.55%, P < 0.001). Main outcome measure. Recruitment of MTB-specific T cells to the site of infection yielded a sensitivity of 100% and specificity of 90%, irrespective of the compartment affected. Conclusions. The accumulation of MTB-specific T cells at the site of infection may prove as useful diagnostic marker for an accurate and rapid diagnosis of active TB. Design. In this cohort study, the frequency of MTBspecific, interferon (IFN)-c expressing CD4 + T cells Keywords: ESAT-6, IFN-c, T cell, tuberculosis. Introduction Tuberculosis (TB) remains one of the leading causes of death affecting more than 8 million persons annually. Although TB it is typically a disease of the lungs, which serves both as port of entry and as the major site of disease manifestation, Mycobacterium tuberculosis (MTB) has the ability to disseminate to various ª 2008 Blackwell Publishing Ltd 1

extrapulmonary sites [1]. To date, diagnosis of pulmonary TB relies on either time-consuming (culture) or insensitive (microscopy) methods often leading to deferred initiation of treatment. Tuberculous pleuritis and tuberculous meningitis share that direct detection of MTB by acid fast staining is hampered by slow numbers of bacteria leading to unacceptably low sensitivity for direct bacillary detection and PCR [2, 3]. The clinical course of MTB infection is characterized to a large extent by the interaction of T cells with MTB-harbouring macrophages. Most importantly, MTB-specific T cells are recruited and clonally expand at the site of infection [4, 5]. Recently introduced enzyme-linked immunospot and ELISA have been developed to rapidly detect MTBspecific T cells using the MTB-specific antigen early secretory antigenic target (ESAT)-6. ESAT-6-specific T cells in peripheral blood are shown to be an accurate marker of infection. However, distinction between active and latent TB is not possible by the assessment of ESAT-6 specific T cells in peripheral blood [6, 7]. In this report, we tested the hypotheses that ESAT-6 specific T cells are accumulated at the site of infection and may serve as rapid and accurate diagnostic marker for active TB. Patients and methods Patients Patients presenting with signs and symptoms suggestive for TB were eligible for this study. Patient recruitment was confined to the wards of the Medical University of Vienna (Department for Infectious Diseases and Respiratory Medicine) and the Department of Respiratory and Critical Care Medicine at the Otto-Wagner Hospital in Vienna, Austria. Biological samples were obtained by broncho-alveolar lavage (broncho-alveolar fluid, n = 11) or puncture (pleural effusion, n = 7; ascites, n = 1; arthritis, n = 1). Cerebrospinal fluid was assessed in case of suspected tuberculous meningitis (n = 5). Investigators performing laboratory procedures were blinded with regards to other diagnostic procedures for TB. Active TB was defined by the presence of either of the following criteria: detection of acid-fast bacilli in Ziehl Neelsen staining of sputum or aspirates, chest X-rays or computed tomography unambiguous signs for TB, positive mycobacterial PCR, necrotizing granulomatous inflammation without other causes, clinical response to tuberculostatic drugs and clinical history suggestive of active TB, including at least three of the following symptoms: night sweat, cough lasting for more than 3 weeks, unintended weight loss, malaise, fever, lassitude and known exposure to open TB. Written informed consent was obtained from all participating individuals. Ethical clearance was given by the Ethics Committee of the Medical University of Vienna and the Viennese KAV. Methods Peripheral blood mononuclear cells (PBMCs) were isolated from heparinized blood by Ficoll-diatrizoate centrifugation. Cells obtained from the site of disease were filtered through a 100 lm membrane (Becton Dickinson, Mountain View, CA, USA), spinned down and washed twice in phosphate-buffered saline. The following assay procedures were equal for both PBMC and cells from the site of disease: cells were cultured in ultra culture medium (Bio Whittaker, Walkersville, MD, USA) supplemented with l-glutamine (2 mmol L )1 ; Sigma, St. Louis, MI, USA), gentamicin (170 mg L )1 ; Sigma) and 2-mercaptoethanol (3.5 ll L )1 ; Merck, Darmstadt, Germany) and plated out in 24-well cell culture plates at 2 10 6 per well. Cells were stimulated with ESAT-6 (Statens Serum Institute, Copenhagen, Denmark) (final concentration, 5 lg ml )1 ). To amplify T-cell receptor signalling and to facilitate the initial phase of T-cell activation, the co-stimulatory mab CD28 (R&D Systems, Minneapolis, MN, USA) was added at a final concentration of 5 lg ml )1. Cells cultured without antigen served as negative controls. Cells were stimulated for 18 h at 37 C in5%co 2, brefeldin A (Sigma, final concentration, 10 lg ml )1 ) was added after 6 h to block protein secretion. Cells were then harvested on ice, fixed with 2% formalde- 2 ª 2008 Blackwell Publishing Ltd Journal of Internal Medicine

hyde and resuspended in Hank s balanced salt solution (Sigma), supplemented with bovine serum albumin (0.3%) and sodium acid (0.1%). Four colour staining was performed with mouse or rat anti-human-mab and the respective isotype controls labelled with fluorescein-isothiocyanate (FITC), phycoerythrin (PE), allophycocyanin (APC) and peridinin chlorophyll (PerCP). Cell walls were permeabilized with saponin (0.1%) (Sigma), resuspended with 50 ll of saponin-buffered antibody dilutions and incubated for 25 min and protected from light exposure. The following mab were used: anti-ifn-c [clone: B27] (FITC-labelled), anti-tumour necrosis factor (TNF)-a [clone: mab11] (PE-labelled) (both obtained from Pharmingen, San Diego, CA, USA); anti-cd4 [clone: RPA-T4] (APC-labelled), anti-cd8 [clone: SK1] (PerCP-labelled) (both purchased from Becton Dickinson). Appropriate antibody dilutions were detected by titration and turned out to be 1 : 50 for anti-cd4, 1 : 20 for anti-cd8, 1 : 100 for anti-tnf-a and 1 : 1000 for interferon (IFN-c). Cells were gated by their forward-side scatter characteristics and additionally defined as CD4 + and CD8 + cells. Cells fulfilling both criteria (lymphocyte and CD4 + or CD8 + ) were further analysed for their cytokine production pattern. At least 10 5 cells were measured. Data were analysed with Cell Quest software (Becton Dickinson) and results were expressed as the percentage of cytokine-producing cells in the CD4 + and CD8 + population. To assure specificity, spontaneous cytokine production of the controls was subtracted from cytokine production of the stimulated cells. Statistical analysis was performed using a commercially available software package (spss 13.0 for Windows; SPSS Inc., Chicago, IL, USA). Wilcoxon Mann Whitney U-test was applied for group differences. Results In all, 25 patients (7 female) were included in this study (median age 47, 18 84). Fifteen patients (Table 1) were classified as having active TB accord- Table 1 Patient characteristics Country Patient Age Sex of origin Final diagnosis Confirmation of TB of T cells Enrichment 1 27 w Pakistan TB Yes (culture) BAL [2.44] 2 32 m Pakistan TB No (granulomatous pneumonia) BAL 28.5 [1.71] 3 18 w Unknown TB Yes (culture) BAL 28 [0.56] 4 34 m Peru TB Yes (culture) BAL 29.4 [4.71] 5 21 m India TB No BAL [1.81] 6 47 m Austria TB of the joint No (granulomatous inflammation) Joint fluid [0.64] 7 26 m Turkey peritoneal TB Yes (culture) Ascites [6.55] 8 84 m Austria TB No (lymphocytic exsudate) Pleural fluid 103.25 [53.69] 9 18 w Pakistan Tuberculous meningitis Yes (culture) CSF [3.42] 10 21 m Turkey Tuberculous meningitis Yes (culture) CSF 5 [0.15] 11 48 m Austria TB Yes (culture) Pleural fluid 138.5 [2.77] 12 52 m Austria TB Yes (culture) Pleural fluid 13.5 [1.22] 13 56 m Turkey TB Yes (culture) BAL [0.64] 14 18 m India TB No (pleuritis) Pleural fluid 531 [5.31] 15 52 m India TB No (lymphocytic exsudate) Pleural fluid 7.25 [0.29] IFN, interferon; MTB, Mycobacterium tuberculosis; TB, tuberculosis; BAL, broncho-alveolar lavage; CSF, cerebrospinal fluid; w, women; m, men. Response at the site of infection without peripheral reactivity was interpreted as positive. Percentage of CD4 + T cells producing MTB-specific IFN-c at the site of infection reported in brackets. Origin ª 2008 Blackwell Publishing Ltd Journal of Internal Medicine 3

ing to routine diagnostic methods (acid-fast bacilli in sputum: n = 6; culture positive: n = 9; PCR-positive: n = 6). TB patients were suffering from other diseases (pneumonia, n = 2; lung cancer, n = 2; rheumatoid arthritis, n = 1; fever of unknown origin, n = 1; meningitis because of Listeria monocytogenes, n = 1; neuroborreliosis, n = 1; unspecified inflammation of the central nervous system, n = 1; chronic obstructive pulmonary disease, n = 1). Interferon-c producing CD4 + T cells were detectable at the site of infection (median: 1.81%, range: 0.29 6.55%) in all patients diagnosed with active TB (Fig. 1). Nine participants suffering from TB (60%) showed reactivity of CD4 + T cells after ESAT-6 stimulation in peripheral blood (median: 0.02%, range: 0.02 0.52%). Amongst patients, a striking increase of ESAT-6-specific T cells was detectable at the site of infection when compared with peripheral blood (median of increase: 28.5-fold, range: 7.25 531 fold; P < 0.001 compared to peripheral blood). The flow cytometry assay was interpreted as positive when 0.02% of CD4 + T cells were expressing IFN-c following ESAT-6 stimulation. To assure specificity, spontaneous cytokine production in unstimulated control wells was subtracted from cytokine production after stimulation with ESAT-6. Enrichment at the site of infection was interpreted as positive, if the frequency of ESAT-6-specific IFN-c-expressing T cells at the site of infection was at least two times higher than in peripheral blood. Likewise, any response at the site of disease without peripheral reactivity was interpreted as positive. In the control group, three individuals (33.3%) showed significant IFN-c responses in CD4 + T cells from peripheral blood after ESAT-6 stimulation Fig. 1 Enrichment of Mycobacterium tuberculosis (MTB)-specific T cells at the site of infection. (a) Representative two parameter dot plots displaying the frequency of MTB-specific CD4 + T cells from peripheral circulation (blood) and from site of infection (lung). Cells were stimulated with early secretory antigenic target and MAb CD28. Numbers indicate the percentage of interferon (IFN)-c producing CD4 + T cells. (b) Enrichment of MTB-specific, IFN-c producing CD4 + T cells at the site of infection (n = 15) compared with peripheral blood during active tuberculosis. The response of individual pairs is linked on the graph by jittered lines. MTB-specific T cells are increased at the site of disease (median of increase: 28.5-fold, range: 7.25 531 fold). TNF-a, tumour necrosis factor. 4 ª 2008 Blackwell Publishing Ltd Journal of Internal Medicine

(0.02%, 0.05% and 0.09%, respectively). However, two of them did not display any enrichment of MTBspecific T cells at the site of infection. The third one with an 11-fold enrichment of T cells at the site of infection was assigned to the control group because of negative results in routine diagnostic tests. Staining of CD4 + T cells with TNF-a in addition to IFN-c was not associated with a higher diagnostic accuracy, as was staining with CD8 (data not shown). Sensitivity and specificity of our in-house assay was 100% and 90%, respectively. Discussion To date, diagnosis of active TB is difficult and time consuming. Recently implemented novel immunological in vitro assays have failed to discern between latent and active disease [6 8]. In patients with pulmonary affection, broncho-alveolar cells but not PBMCs showed enhanced reactivity towards mycobacterial antigens [4, 5]. Thus, it is suggestive that whilst only a small number of MTB-specific T cells are found in peripheral circulation, highly activated, antigen-specific effector T cells accumulate at disease site and rapidly produce Th-1-type cytokines [4, 5, 9 12]. In this report, we assessed an in-house cell culture assay followed by flow cytometry to enumerate the percentage of CD4 + T cells obtained from the site of infection producing IFN-c after ESAT-6 stimulation. Our data indicate that the preferential recruitment of CD4 + T cells may allow distinguishing between patients with active TB and those with nontuberculous diseases. MTB-specific IFN-c response in peripheral blood was low amongst patients (60%) with active TB, well corresponding to recent findings [8]. In contrast, patients suffering from active TB showed a striking enrichment of MTB-specific T cells at the site of infection. Interestingly, 3 out of 10 patients with other diseases than TB showed IFN-c responses after ESAT-6 stimulation. Two of them had no accumulation of MTB-specific T cells at the site of infection detectable. This finding underlines the hypothesis that the hallmark of active disease is not the presence of MTB-specific T cells in peripheral blood but rather the accumulation of these cells at the compartment affected. Thus, the reactivity of T cells to MTBspecific antigens such as ESAT-6 in peripheral blood without enrichment at the site of disease is indicative of latent infection but not active TB. Currently, diagnostic standards for active TB are far from perfect. This may also be seen as limitation in our study as the lack of a reliable gold standard further complicates thorough assessment of novel diagnostic approaches. Further drawbacks of our method include the need for invasive procedures to obtain biological samples from the site of infection. This may prove as practical limitation for many resource poor settings where TB is of high public health importance. However, the fact that our novel diagnostic approach provides definite results within 24 h may per se be seen as a major potential advantage, for example, in case of tuberculous meningitis, where early treatment is mandatory. We conclude that in line with recent findings [9 12] for routine purposes, enumeration of MTB-specific, IFN-c secreting CD4 + T cells from the site of infection can provide a new tool to tremendously accelerate diagnosis of active TB. Conflict of interest statement The authors declare no conflict of interest. There was no financial support by companies. Acknowledgements The investigators want to thank the study participants. Stefan Winkler and Johannes Nemeth had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. References 1 World Health Organization (WHO). Tuberculosis facts 2007. Available at http://www.who.int/tb/en/, accessed 18 August 2008. 2 Light RW. Pleural effusion. N Engl J Med 2002; 346: 1971. 3 Thwaites GE, Tran TH. Tuberculous meningitis: many questions, too few answers. Lancet Neurol 2005; 4: 160 70. ª 2008 Blackwell Publishing Ltd Journal of Internal Medicine 5

4 Barnes PF, Mistry SD, Cooper CL et al. Compartmentalization of a CD4+ T lymphocyte subpopulation in tuberculous pleuritis. J Immunol 1989; 142: 1114 9. 5 Schwander SK, Torres M, Sada E et al. Enhanced responses to Mycobacterium tuberculosis antigens by human alveolar lymphocytes during active pulmonary tuberculosis. J Infect Dis 1998; 178: 1434 45. 6 Lalvani A, Pathan AA, Durkan H et al. Enhanced contact tracing and spatial tracking of Mycobacterium tuberculosis infection by enumeration of antigen-specific T cells. Lancet 2001; 357: 2017 21. 7 Menzies D, Pai M, Comstock G. Meta-analysis: new tests for diagnosis of latent tuberculosis infection: areas of uncertainty and recommendations for research. Ann Intern Med 2007; 146: 340 54. 8 Dewan PK, Grinsdale J, Kawamura LM. Low sensitivity of a whole-blood interferon-gamma release assay for detection of active tuberculosis. Clin Infect Dis 2007; 44: 69 73. 9 Lalvani A, Pathan AA, McShane H et al. Rapid detection of Mycobacterium tuberculosis infection by enumeration of antigen-specific T cells. Am J Respir Crit Care Med 2001; 163: 824 8. 10 Jafari C, Ernst M, Kalsdorf B et al. Rapid diagnosis of smear-negative tuberculosis by bronchoalveolar lavage enzyme-linked immunospot. Am J Respir Crit Care Med 2006; 174: 1048 54. 11 Wilkinson KA, Wilkinson RJ, Pathan A et al. Ex vivo characterization of early secretory antigenic target 6-specific T cells at sites of active disease in pleural tuberculosis. Clin Infect Dis 2005; 40: 184 7. 12 Losi M, Bossink A, Codecasa L et al. European Tuberculosis Network (TBNET). Use of a T-cell interferon-gamma release assay for the diagnosis of tuberculous pleurisy. Eur Respir J 2007; 30: 1173 9. Correspondence: Johannes Nemeth, Division of Infectious Diseases and Tropical Medicine, Department of Medicine I, Medical University of Vienna, Vienna, Austria. (fax: +41 61 26 55715; e-mail: nemethj@uhbs.ch). 6 ª 2008 Blackwell Publishing Ltd Journal of Internal Medicine